OpiCalc Logo

OpiCalc

--- Clinical Tools

Logo
OpiCalc
APGAR ScoreAssisted Delivery (FIGO)BPP (Manning Score)Bishop ScoreCARPREG II Cardiac RiskCervical Cancer StagingContraceptive Pearl IndexDoppler Matrix (UA/MCA)EFW (Hadlock)Endometrial StagingEndometrial ThicknessFGR Criteria (Consensus)FSFI (Sexual Function)Ferriman-Gallwey ScoreFetal Anemia (MCA PSV)GDM Diagnostic CriteriaGPA History IndicatorGail Model Breast RiskGestational Dating (LMP)HIV PMTCT ProtocolIOTA Simple RulesIVF Due Date & AMHIron Deficit (Ganzoni)Labour Progress (WHO)Maternal Sepsis (qSOFA)O-RADS ClassificationOvarian Cancer StagingPAS Hemorrhage RiskPPH Protocol (FIGO)Preeclampsia (ACOG)Rho(D) Dose (K-B)Rotterdam PCOS CriteriaSyphilis ManagementTORCH FrameworkVBAC Success ProbabilityVulvar Cancer StagingWeight Gain (IOM)mWHO Cardiac Risk

Vulvar Cancer Staging

FIGO Vulvar Staging (2021)

Updated Nodes Classification

I

Confined to Vulva/Perineum

IA (≤2cm, ≤1mm invasion) | IB (>2cm or >1mm invasion)

II

Adjacent Tissue Extension

Lower 1/3 Urethra, Vagina, or Anus (Nodes Negative)

III

Positive Regional Nodes

IIIA (1 node ≥5mm or 1–2 nodes <5mm) | IIIB (2+ nodes ≥5mm) | IIIC (Extracapsular spread)

IV

Upper Tract / Distant

IVA (Upper 2/3 Urethra/Vagina, Bladder/Rectum mucosa) | IVB (Distant Metastasis)

The 2021 update refined the Prognostic Node groups (Stage III) based on absolute node size and extracapsular spread.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Clinical Uses

  • Surgical/pathological staging of primary vulvar squamus cell carcinoma and melanomas
  • Major determinant for the extent of inguinofemoral lymph node dissection
  • Guiding the necessity for adjuvant groin/pelvic radiotherapy

The 2021 Update

The 2021 FIGO update made critical modifications regarding lymph node morphology. Extracapsular spread (ECS) in the groin nodes is now officially recognized as overwhelmingly prognostic and immediately upstages the patient to IIIC.

CLINICAL INSIGHT

How it Works

Stage I — Confined to Vulva/Perineum (No Nodal Spread)

IA
IB

Stage II — Local Adjacent Spread (No Nodal Spread)

II

Stage III — Inguinofemoral Lymph Nodes

IIIA
IIIB
IIIC

Stage IV — Deep Regional or Distant Spread

IVA
IVB
CLINICAL INSIGHT

Practical Pearls

Nodal Nuances

  • Groin node status is the single most important prognostic factor for overall survival.
  • Note that pelvic lymph node involvement (iliac/obturator) bypasses Stage III completely and is classified as Stage IVB (distant metastasis).
  • Stage IA patients have an essentially zero risk of nodal metastases. They strictly require wide local excision only and should be spared the severe morbidity of groin dissection.
CLINICAL INSIGHT

Next Steps

Surgical Management Guidelines

  • Stage IA: Wide local excision (WLE). Observation of groins.
  • Stage IB / II (Lateral tumor, >2cm from midline): WLE + ipsilateral inguinofemoral lymph node evaluation (or Sentinel Lymph Node biopsy).
  • Stage IB / II (Central tumor, <2cm from midline): WLE + bilateral inguinofemoral lymph node evaluation.
  • Positive Sentinel Node or ECS: Proceed to full genitofemoral lymphadenectomy and immediate planning for adjuvant groin/pelvic radiotherapy.
CLINICAL INSIGHT

Evidence Base

Current Guidelines

FIGO staging for carcinoma of the vulva: 2021 revision.

Olawaiye AB, Cuello MA, Syed AA, et al.Int J Gynaecol Obstet.2021
CLINICAL INSIGHT

Background

Historical Context

Prior to the 1990s, vulvar cancer was uniformly treated by the brutal "en bloc" radical vulvectomy with bilateral groin dissections. Modern staging allows for highly targeted, tissue-sparing surgery to prevent catastrophic lymphedema while maintaining survival rates.